Predict your next investment

Morphogenesis company logo
HEALTHCARE | Biotechnology
morphogenesis-inc.com

See what CB Insights has to offer

Stage

Unattributed VC | Alive

Total Raised

$22.61M

Last Raised

$2.68M | 9 mos ago

About Morphogenesis

Morphogenesis is a clinical stage company developing cell and gene therapies based on distinct and synergistic technology platforms. The company's mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.

Morphogenesis Headquarter Location

10500 University Center Drive Suite 110

Tampa, Florida, 33612,

United States

813-875-6600

Latest Morphogenesis News

Morphogenesis Receives Federal Funding for Cervical Cancer Therapeutic Treatment

Jul 7, 2021

Morphogenesis, Inc. recently received federal funding for a cervical cancer therapeutic drug they are developing for low resource populations in countries with limited healthcare infrastructure. The National Cancer Institute and the National Institutes of Health awarded the $400,000 grant, after the company’s Small Business Innovation Research (SBIR) proposal received high scores. Grit Daily caught up […] / share Published on July 7, 2021 Morphogenesis, Inc. recently received federal funding for a cervical cancer therapeutic drug they are developing for low resource populations in countries with limited healthcare infrastructure. The National Cancer Institute and the National Institutes of Health awarded the $400,000 grant, after the company’s Small Business Innovation Research (SBIR) proposal received high scores. Grit Daily caught up with Morphogenesis CEO Dr. Patricia Lawman , to discuss the funding, which was awarded in partnership with the pharmaceutical compounding company, Medisca . Dr. Lawman says, “Cervical cancer is one of the biggest problems for women across the world—in Africa, in India—it’s really one of the highest causes for death.” The therapeutic treatment , IFx-Hu2.0, is currently administered via direct injection into the tumor, but low-resource communities may not have easy access to imaging software that would make such injection feasible. Therefore, Morphogenesis’ scientists are working on a way to keep the nucleic acid compound from degrading in warmer temperatures. The team’s ultimate goal is to make the therapy easy enough for women to treat themselves. There are a lot of factors for the research team to consider when treating low resource populations. Dr. Lawman says, “There are logistical issues of whether there’s a clinic whether there’s equipment at a clinic, whether there’s training staff at the clinic and then whether people can even get to a clinic. So we wanted to try our best to be able to address all these issues.” The team aims to make something that all women, regardless of their situation, can access. The grant funds were awarded in April, and Dr. Lawman reports that the team is already making good progress. Most SBIR grants come in 2 installments of $150,000 over 6-month periods, but the $400,000 grant awarded to Morphogenesis allows for research over a full year term. When the team has created a compound that can remain stable at higher temperatures, they will apply for phase 2, which offers funding up to $2M. At that stage, they will run clinical trials, likely within the U.S. To run trials in their low resource countries of interest, India and South Africa, the group will have to negotiate with the host countries’ FDA (or its equivalent agency,) after getting the proper licensing, to run trials on populations there. The prevalence of cervical cancer in the U.S. has decreased over the past 40 years due to women getting regular Pap smears, as well as the development and widespread administration of the HPV vaccine. In poorer countries, access to such medical tests remains comparatively low. There are low resource communities within the U.S. that could benefit from an easily administered cervical cancer therapeutic treatment, but the research being done on IFx-Hu2.0 to make it widely accessible could have positive implications for women all over the world. Tags

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Morphogenesis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Morphogenesis is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,762 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Morphogenesis Patents

Morphogenesis has filed 11 patents.

The 3 most popular patent topics include:

  • Vaccines
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/26/2019

8/25/2020

Immunology, Immune system, Clusters of differentiation, Vaccines, Oncology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/26/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/25/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Immune system, Clusters of differentiation, Vaccines, Oncology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Morphogenesis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Morphogenesis Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.